10578826a

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	5	AUG 24	CA/CAplus enhanced with legal status information for U.S. patents
NEWS	6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS	7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS	8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS	9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS	10	OCT 27	Free display of legal status information in CA/CAplus, USPATFULL, and USPAT2 in the month of November.
NEWS	11	NOV 23	Addition of SCAN format to selected STN databases
NEWS	12	NOV 23	Annual Reload of IFI Databases

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:49:45 ON 23 NOV 2009

```
=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 12:50:07 ON 23 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   22 NOV 2009  HIGHEST RN 1193309-59-9
DICTIONARY FILE UPDATES:  22 NOV 2009  HIGHEST RN 1193309-59-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10578826a.str
```





chain nodes :
8 9 11 13
ring nodes :
1 2 3 4 5
chain bonds :
3-11 5-8 8-9 8-13
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 3-11 5-8
exact bonds :
2-3 3-4 4-5 8-9 8-13
isolated ring systems :
containing 1 :

G1:S,CH

G2:C,N

G3:Ph,Cy,Hy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 8:CLASS 9:CLASS 11:CLASS 13:CLASS

L1 STRUCTURE UPLOADED

```
=> d l1
L1 HAS NO ANSWERS
L1              STR
```



G1 S,CH

G2 C,N

G3 Ph,Cy,Hy

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 12:50:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     5512 TO ITERATE

 36.3% PROCESSED     2000 ITERATIONS                                4 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       105788 TO   114692
PROJECTED ANSWERS:              21 TO      419

L2            4 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 12:50:32 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   111035 TO ITERATE

100.0% PROCESSED   111035 ITERATIONS                             229 ANSWERS
SEARCH TIME: 00.00.07

L3          229 SEA SSS FUL L1

=>
Uploading C:\Program Files\Stnexp\Queries\10578826b.str
```





chain nodes :
8 10 12 19
ring nodes :
1 2 3 4 5 13 14 15 16 17 18
chain bonds :
3-10 5-8 8-12 8-18 15-19
ring bonds :
1-2 1-5 2-3 3-4 4-5 13-14 13-18 14-15 15-16 16-17 17-18
exact/norm bonds :
1-2 1-5 3-10 5-8 8-18 15-19
exact bonds :
2-3 3-4 4-5 8-12
normalized bonds :
13-14 13-18 14-15 15-16 16-17 17-18
isolated ring systems :
containing 1 : 13 :

G1:S,CH

G2:C,N

G3:Ph,Cy,Hy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 8:CLASS 10:CLASS 12:CLASS 13:Atom
14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom

L4 STRUCTURE UPLOADED

=> d l4
L4 HAS NO ANSWERS
L4 STR



G1 S,CH

G2 C,N

G3 Ph,Cy,Hy

Structure attributes must be viewed using STN Express query preparation.

=> s l4
SAMPLE SEARCH INITIATED 12:54:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5511 TO ITERATE

36.3% PROCESSED 2000 ITERATIONS 1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 105768 TO 114672
PROJECTED ANSWERS: 1 TO 154

L5 1 SEA SSS SAM L4

=> s l4 sss full
FULL SEARCH INITIATED 12:54:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 110997 TO ITERATE

100.0% PROCESSED 110997 ITERATIONS 9 ANSWERS
SEARCH TIME: 00.00.07

L6 9 SEA SSS FUL L4

=> FIL HCAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	374.64	374.86

FILE 'HCAPLUS' ENTERED AT 12:54:51 ON 23 NOV 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 23 Nov 2009 VOL 151 ISS 22
FILE LAST UPDATED: 22 Nov 2009 (20091122/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

During November, try the new LSUS format of legal status information in the CA/CAplus family databases for free! Complete details on the number of free displays and other databases participating in this offer appear in NEWS 10.

```
=> d his

     (FILE 'HOME' ENTERED AT 12:49:45 ON 23 NOV 2009)

     FILE 'REGISTRY' ENTERED AT 12:50:07 ON 23 NOV 2009
L1             STRUCTURE UPLOADED
L2               4 S L1
L3             229 S L1 SSS FULL
L4             STRUCTURE UPLOADED
L5               1 S L4
L6               9 S L4 SSS FULL

     FILE 'HCAPLUS' ENTERED AT 12:54:51 ON 23 NOV 2009

=> s l3
L7            75 L3
```

```
=> s l6
L8           3 L6

=> s l7 and py<=2003
      24045074 PY<=2003
L9           53 L7 AND PY<=2003

=> s l8 and py<=2003
      24045074 PY<=2003
L10           0 L8 AND PY<=2003

=> s l9 and p/dt
       6945565 P/DT
L11          27 L9 AND P/DT

=> s l11 and us/pc
       2005581 US/PC
L12          14 L11 AND US/PC

=> d l8 ibib abs hitstr tot

L8   ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2008:1367952  HCAPLUS
DOCUMENT NUMBER:          149:534221
TITLE:                    Preparation of thiazolyl-substituted
                          imidazolylphenylamine derivatives and related
                          compounds as modulators of amyloid beta
INVENTOR(S):              Baumann, Karlheinz; Flohr, Alexander; Jacobsen,
                          Helmut; Jolidon, Synese; Luebbers, Thomas
PATENT ASSIGNEE(S):       Germany
SOURCE:                   U.S. Pat. Appl. Publ., 32pp.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     US 20080280948        A1    20081113    US 2008-114852          20080505
     WO 2008138753         A1    20081120    WO 2008-EP55290         20080430
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:                       EP 2007-108004      A  20070511
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S):          MARPAT 149:534221
GI
```



I



II

AB Title compds. I [R1 = H, alkoxy or CN; ring A = (un)substituted thiazolyl; ring B = (un)substituted imidazolyl, 1H-1,2,4-triazolyl or 1H-1,2,3-triazolyl], and their pharmaceutically active acid addition salts, are prepared and disclosed as modulators of amyloid beta. Thus, e.g., II was prepared by cyclization reaction of 3-chloro-4-(3-chlorophenyl)-2-butanone with [3-methoxy-4-(4-methylimidazol-1-yl)phenyl]thiourea which was prepared from 2-chloro-5-nitroanisole and 4-methylimidazole in 4 steps. Selected I were evaluated for their activity to the inhibition of Aβ42 secretion in cellular γ-secretase assay with IC50 values < 1.0 μM, e.g., II exhibited an IC50 value of 0.21 μM. As modulators for amyloid beta and thus, I may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease.

IT 1077629-59-4P, (4,5-Diphenylthiazol-2-yl)[4-(4-methylimidazol-1-yl)phenyl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolyl-substituted imidazolylphenylamine derivs. and related compds. as modulators of amyloid beta)

RN 1077629-59-4 HCAPLUS

CN 2-Thiazolamine, N-[4-(4-methyl-1H-imidazol-1-yl)phenyl]-4,5-diphenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L8 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:805626 HCAPLUS
DOCUMENT NUMBER: 149:128819
TITLE: Preparation of diaminothiazole derivatives as Axl inhibitors
INVENTOR(S): Goff, Dane; Zhang, Jing; Singh, Rajinder; Holland, Sacha
PATENT ASSIGNEE(S): Rigel Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 84pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008080134	A2	20080703	WO 2007-US88717	20071221
WO 2008080134	A3	20080821		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20080227789	A1	20080918	US 2007-963157	20071221
PRIORITY APPLN. INFO.:			US 2006-876963P P	20061222

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 149:128819
GI



I



II

AB Title compds. represented by the formula I [wherein R1, R4, R5 = H, alkyl, aryl(alkyl), etc.; R2 = (un)substituted (hetero)aryl; R3 = (un)substituted heteroaryl; and isolated stereoisomers or mixture thereof, or pharmaceutically acceptable salts thereof] were prepared as inhibitors of receptor protein tyrosine kinase Axl. For example, II was provided in a multi-step synthesis starting from 4-(2-pyrrolidinoethoxy)aniline. I were tested for Axl activity in Phosoho-AKT in-cell western assay. Thus, I and their pharmaceutical compns. are useful for the treatment of diseases or conditions associated with Axl activity.

IT 1035994-50-3P, 5-(Isoquinolin-1-yl)-N-(4-morpholinophenyl)thiazole-2,4-diamine 1035994-56-9P, 5-(6,7-Dimethoxyquinazolin-4-yl)-N-(4-morpholinophenyl)thiazole-2,4-diamine 1035994-58-1P, 5-(6,7-Dimethoxyquinazolin-4-yl)-N-[4-(4-methylpiperazin-1-yl)phenyl]thiazole-2,4-diamine 1035994-60-5P, N-[4-[4-(Bicyclo[2.2.1]heptan-2-yl)piperazin-1-yl]phenyl]-5-(thieno[3,2-d]pyrimidin-4-yl)thiazole-2,4-diamine 1035994-62-7P, N-[4-[4-(Bicyclo[2.2.1]heptan-2-yl)piperazin-1-yl]phenyl]-5-(6,7-dimethoxyquinazolin-4-yl)thiazole-2,4-diamine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaminothiazole derivs. as Axl inhibitors)

RN 1035994-50-3 HCAPLUS

CN 2,4-Thiazolediamine, 5-(1-isoquinolinyl)-N2-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 1035994-56-9 HCAPLUS
CN 2,4-Thiazolediamine, 5-(6,7-dimethoxy-4-quinazolinyl)-N2-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 1035994-58-1 HCAPLUS
CN 2,4-Thiazolediamine, 5-(6,7-dimethoxy-4-quinazolinyl)-N2-[4-(4-methyl-1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 1035994-60-5 HCAPLUS
CN 2,4-Thiazolediamine, N2-[4-(4-bicyclo[2.2.1]hept-2-yl-1-piperazinyl)phenyl]-5-thieno[3,2-d]pyrimidin-4-yl- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 1035994-62-7 HCAPLUS
CN 2,4-Thiazolediamine, N2-[4-(4-bicyclo[2.2.1]hept-2-yl-1-piperazinyl)phenyl]-5-(6,7-dimethoxy-4-quinazolinyl)- (CA INDEX NAME)



L8 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:451371 HCAPLUS
DOCUMENT NUMBER: 142:482040
TITLE: Preparation of thiazole and pyrazole derivatives as Flt-3 kinase inhibitors
INVENTOR(S): Bold, Guido; Floersheimer, Andreas; Furet, Pascal; Guagnano, Vito; Masuya, Keiichi; Vaupel, Andrea; Schoepfer, Joseph
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2005047273		A1	20050526	WO 2004-EP12892	20041112
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004289447		A1	20050526	AU 2004-289447	20041112
CA 2545350		A1	20050526	CA 2004-2545350	20041112
EP 1687285		A1	20060809	EP 2004-818403	20041112
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
BR 2004016039		A	20070102	BR 2004-16039	20041112
CN 1902186		A	20070124	CN 2004-80040374	20041112
JP 2007511484		T	20070510	JP 2006-538814	20041112
MX 2006005356		A	20060710	MX 2006-5356	20060512
KR 2006108673		A	20061018	KR 2006-709281	20060512
IN 2006CN01662		A	20070629	IN 2006-CN1662	20060512
US 20070167449		A1	20070719	US 2006-578826	20061120
AU 2009202639		A1	20090723	AU 2009-202639	20090629
PRIORITY APPLN. INFO.:				GB 2003-26601	A 20031114
				AU 2004-289447	A3 20041112
				WO 2004-EP12892	W 20041112

OTHER SOURCE(S): CASREACT 142:482040; MARPAT 142:482040

GI



I

AB Title compds. I [Q = S and X = C or Q = CH and X = N; R1 = (un)substituted phenyl; R2 = (un)substituted (hetero)aryl] are prepared For instance, [5-phenylthiazol-2-yl][4-[2-(pyrrolidin-1-yl)ethoxy]phenyl]amine (II) is prepared from phenylacetaldehyde and [4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]thiourea (preparation given). II has IC50 = 0.041 μM for Flt-3 kinase. I are useful for the treatment of a proliferative disease, in particular such diseases which respond to inhibition of the Flt-3 kinase.

IT 852045-50-2P 852045-68-2P 852045-78-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazole and pyrazole derivs. as Flt-3 kinase inhibitors)

RN 852045-50-2 HCAPLUS

CN 2-Thiazolamine, 5-(4-methoxyphenyl)-N-[4-(4-methyl-1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 852045-68-2 HCAPLUS
CN 2-Thiazolamine, N-[4-(4-methyl-1-piperazinyl)phenyl]-5-(3-thienyl)- (CA INDEX NAME)



RN 852045-78-4 HCAPLUS
CN 2-Thiazolamine, N-[4-(4-methyl-1-piperazinyl)phenyl]-5-[3-(3-thienyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l12 ibib abs hitstr tot

L12 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:376556 HCAPLUS
DOCUMENT NUMBER: 138:385437
TITLE: Preparation of

	5-(6-oxo-1,6-dihydro-3-pyridazinyl)-4-phenylthiazoles as adenosine receptor antagonists
INVENTOR(S):	Tsutsumi, Hideo; Tabuchi, Seiichiro; Akahane, Atsushi; Yasuda, Hironobu; Omori, Hiroki; Temmaru, Kiyoshi; Zanka, Atsuhiko
PATENT ASSIGNEE(S):	Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE:	PCT Int. Appl., 183 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003039451	A2	20030515	WO 2002-JP11639	20021108 <--
WO 2003039451	A3	20030925		
W: JP, US				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
EP 1441732	A2	20040804	EP 2002-802729	20021108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005510508	T	20050421	JP 2003-541743	20021108
US 20050004134	A1	20050106	US 2004-494033	20040507 <--

PRIORITY APPLN. INFO.:	AU 2001-8749	A	20011108
	AU 2001-9048	A	20011123
	WO 2002-JP11639	W	20021108

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 138:385437

GI



AB Title compds. I [wherein R = (un)substituted 6-oxo-1,6-dihydro-3-pyridazinyl; R1 = (un)substituted Ph; R2 = H, NR4R5, or CXNR8R9; R4 = H, alkyl, or alkenyl; R5 = H, acyl, cycloalkyl, alkenyl, heterocyclyl, or (un)substituted alkyl or aryl; X = O or S; R8 = H or alkyl; R9 = H, cycloalkyl, alkoxy, (di)alkylamino, or (un)substituted alkyl; or NR8R9 = (un)substituted saturated N-containing heterocyclyl; or pharmaceutically acceptable salt thereof] were prepared as adenosine

receptor antagonists. For example, 6-(1-bromo-2-oxo-2-phenylethyl)-2-isopropyl-3(2H)-pyridazinone was coupled with thiourea in EtOH to give 6-(2-amino-4-phenyl-1,3-thiazol-5-yl)-2-isopropyl-3(2H)-pyridazinone, which was amidated to provide II. The latter exhibited adenosine antagonistic activity against A1 and A2a receptors with Ki values of 0.27 nM and 1.46 nM, resp. In addition, administration of 3.2 mg/kg of II completely suppressed haloperidol-induced catalepsy in seven mice. Thus, I are useful for the treatment and/or prevention of numerous diseases, including cardiac and circulatory disorders, degenerative disorders of the central nervous system, respiratory disorders, and many diseases for which diuretic treatment is suitable (no data).

IT 524920-02-3P, 6-(2-Anilino-4-phenyl-1,3-thiazol-5-yl)-2-isopropyl-3(2H)-pyridazinone hydrobromide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(adenosine antagonist; preparation of (oxopyridazinyl)(phenyl)thiazoles as adenosine receptor antagonists for treatment of cardiac, circulatory, degenerative, and respiratory disorders)

RN 524920-02-3 HCAPLUS

CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[4-phenyl-2-(phenylamino)-5-thiazolyl]-, hydrobromide (1:1) (CA INDEX NAME)



● HBr

OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:964216 HCAPLUS
DOCUMENT NUMBER: 138:33356
TITLE: Medicinal compositions as p38MAP kinase and/or TNF-α production inhibitor for pain
INVENTOR(S): Ohkawa, Shigenori; Naruo, Kenichi; Morimoto, Shigeru; Nagase, Yoshinori; Miwatashi, Seiji
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 563 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100433	A1	20021219	WO 2002-JP5726	20020610 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2450400	A1	20021219	CA 2002-2450400	20020610 <--
AU 2002306341	A1	20021223	AU 2002-306341	20020610 <--
JP 2003063993	A	20030305	JP 2002-168226	20020610 <--
EP 1402900	A1	20040331	EP 2002-733431	20020610
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20050080113	A1	20050414	US 2003-480551	20031211 <--

PRIORITY APPLN. INFO.:

JP 2001-175224	A	20010611
JP 2001-175273	A	20010611
WO 2002-JP5726	W	20020610

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 138:33356

AB Prevention/treatment for pain and/or suppression of the activation and/or inhibition of the formation of osteoclasts by using a p38MAP kinase inhibitor and/or a TNF-α production inhibitor. A method of HDL1 relieving a P 450-inhibitory effect of a compound having a pyridyl group or its salt characterized by introducing a substituent into the α-position of the nitrogen atom in the pyridyl group of the above compound or its salt, or for relieving a P 450-inhibitory effect of a compound having a pyridyl group and an aromatic hydrocarbyl group or its salt characterized by introducing a polar group into the aromatic hydrocarbyl group of the above compound or its salt.

IT 97422-54-3 97422-55-4 97422-56-5
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal compns. as p38MAP kinase and/or TNF-α production inhibitor for pain)

RN 97422-54-3 HCAPLUS
CN 2-Thiazolamine, 4-(4-methoxyphenyl)-N-phenyl-5-(3-pyridinyl)- (CA INDEX NAME)



RN 97422-55-4 HCAPLUS

CN 2-Thiazolamine, N-phenyl-5-(3-pyridinyl)-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 97422-56-5 HCAPLUS
CN Phenol, 4-[2-(phenylamino)-5-(3-pyridinyl)-4-thiazolyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2002:504649 HCAPLUS
DOCUMENT NUMBER: 137:83638
TITLE: Concomitant drugs of p38MAP kinase inhibitors and/or TNF-α production inhibitors with other specified agents
INVENTOR(S): Ohkawa, Shigenori; Naruo, Kenichi; Miwatashi, Seiji
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 278 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051442	A1	20020704	WO 2001-JP11353	20011225 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2436739 A1 20020704 CA 2001-2436739 20011225 <--
AU 2002217493 A1 20020708 AU 2002-217493 20011225 <--
JP 2002302458 A 20021018 JP 2001-392778 20011225 <--
EP 1354603 A1 20031022 EP 2001-271876 20011225 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 20040097555 A1 20040520 US 2003-451839 20030625 <--
PRIORITY APPLN. INFO.: JP 2000-396220 A 20001226
JP 2001-27572 A 20010202
WO 2001-JP11353 W 20011225
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 137:83638
AB Drugs comprising a combination of one or more p38MAP kinase inhibitors and/or TNF-α production inhibitors with one or more agents selected from the group consisting of: (1) nonsteroidal anti-inflammatory agents; (2) disease-modification antirheumatics; (3) anti-cytokine drugs; (4) immunomodulators; (5) steroidal drugs; and (6) c-JUN N-terminal kinase inhibitors. These concomitant drugs are useful as preventives and remedies for diseases such as rheumatism and arthritis and other diseases. For example, tablets containing [4-(3,5-dimethylphenyl)-5-(2-phenylmethyloxy-4-pyridyl)-1,3-thiazol-2-yl]amine 50 mg/tablet are administered with tablets containing rofecoxib 5 mg/tablet.
IT 97422-54-3P 97422-55-4P 97422-56-5P
224038-79-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(combination drugs containing p38MAP kinase inhibitors and/or TNF-α production inhibitors with other specified agents)
RN 97422-54-3 HCAPLUS
CN 2-Thiazolamine, 4-(4-methoxyphenyl)-N-phenyl-5-(3-pyridinyl)- (CA INDEX NAME)



RN 97422-55-4 HCAPLUS
CN 2-Thiazolamine, N-phenyl-5-(3-pyridinyl)-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 97422-56-5 HCAPLUS
CN Phenol, 4-[2-(phenylamino)-5-(3-pyridinyl)-4-thiazolyl]- (CA INDEX NAME)



RN 224038-79-3 HCAPLUS
CN 2-Thiazolamine, 4-(4-methoxyphenyl)-N-phenyl-5-(4-pyridinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)
REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:581702 HCAPLUS
DOCUMENT NUMBER: 135:166823
TITLE: Preparation of 2,4-diaminothiazoles as GSK-3 inhibitors
INVENTOR(S): Bowler, Andrew Neil; Olesen, Preben Houlberg; Sorensen, Anders Robert; Hansen, Bo Falck; Worsaae, Helle; Kurtzhals, Peter
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001056567	A1	20010809	WO 2001-DK73	20010201 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,

SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 20010039275 A1 20011108 US 2001-774900 20010131 <--
PRIORITY APPLN. INFO.: DK 2000-187 A 20000204
US 2000-183518P P 20000218
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 135:166823
GI



I

AB The title compds. [I; E = alkyl, alkenyl, alkoxy, etc.; A = a bond, alkylene, CO; B = a bond, CO, SO, etc.; D = OH, halo, CN, etc.] which inhibit GSK-3 (glycogen synthase kinase-3) and which are useful for the treatment and/or prevention disorders and diseases wherein an inhibition of GSK-3 is beneficial, especially especially Alzheimer's disease, bipolar disorder, IGT (impaired glucose tolerance), Type 1 diabetes, Type 2 diabetes and obesity, were prepared and formulated. Thus, reacting 2-bromo-1-cyclopropylethanone with 1-phenyl-3-guanylthiourea afforded I [E = Ph; A = a bond; B = CO; D = cyclopropyl] which showed IC50 of < 5 μM against GSK-3.

IT 1102226-90-3 1102226-91-4 1102226-93-6
RL: PRPH (Prophetic)
(Preparation of 2,4-diaminothiazoles as GSK-3 inhibitors)

RN 1102226-90-3 HCAPLUS
CN 2,4-Thiazolediamine, 5-(4-bromophenyl)-N2-phenyl- (CA INDEX NAME)



RN 1102226-91-4 HCAPLUS
CN 2,4-Thiazolediamine, 5-(2,4-difluorophenyl)-N2-phenyl- (CA INDEX NAME)



RN 1102226-93-6 HCAPLUS
CN 2,4-Thiazolediamine, N2-phenyl-5-(3-pyridinyl)- (CA INDEX NAME)



IT 353512-03-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2,4-diaminothiazoles as GSK-3 inhibitors)
RN 353512-03-5 HCAPLUS
CN 2,4-Thiazolediamine, 5-(4-nitrophenyl)-N2-phenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:115147 HCAPLUS
DOCUMENT NUMBER: 134:163031
TITLE: Preparation of thiazole derivatives as p38MAP kinase inhibitors and inhibitors of TNF-α production

INVENTOR(S): Ohkawa, Shigenori; Naruo, Kenichi; Kimura, Hiroyuki; Miwatashi, Seiji
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 166 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001010865	A1	20010215	WO 2000-JP5198	20000803 <--
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2381215	A1	20010215	CA 2000-2381215	20000803 <--
EP 1205478	A1	20020515	EP 2000-951874	20000803 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2001114690	A	20010424	JP 2000-242761	20000804 <--
US 6962933	B1	20051108	US 2002-48937	20020206 <--

PRIORITY APPLN. INFO.: JP 1999-224651 A 19990806
WO 2000-JP5198 W 20000803
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 134:163031

AB Claimed are p38MAP kinase inhibitors containing 1,3-thiazole compds. (substituted by optionally substituted pyridyl at the 5-position), or salts or prodrugs thereof. Compds. of this invention in vitro showed IC50 values of 0.086 μM to 0.63 μM against p38MAP kinase. Formulations are given.

IT 97422-54-3P 97422-55-4P 97422-56-5P
224038-79-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazole derivs. as p38MAP kinase inhibitors and inhibitors of TNF-α production)

RN 97422-54-3 HCAPLUS
CN 2-Thiazolamine, 4-(4-methoxyphenyl)-N-phenyl-5-(3-pyridinyl)- (CA INDEX NAME)



RN 97422-55-4 HCAPLUS

CN 2-Thiazolamine, N-phenyl-5-(3-pyridinyl)-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 97422-56-5 HCAPLUS
CN Phenol, 4-[2-(phenylamino)-5-(3-pyridinyl)-4-thiazolyl]- (CA INDEX NAME)



RN 224038-79-3 HCAPLUS
CN 2-Thiazolamine, 4-(4-methoxyphenyl)-N-phenyl-5-(4-pyridinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 21 THERE ARE 21 CAPLUS RECORDS THAT CITE THIS RECORD (34 CITINGS)
REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:881130 HCAPLUS
DOCUMENT NUMBER: 134:42124
TITLE: Preparation of diaminothiazoles for inhibiting protein kinases
INVENTOR(S): Chu, Shao Song; Alegria, Larry Andrew; Bender, Steven Lee; Benedict, Suzanne Pritchett; Borchardt, Allen J.; Kania, Robert Steve; Nambu, Mitchell David; Tempczyk-Russell, Anna Maria; Sarshar, Sepehr
PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 397 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
WO 2000075120	A1	20001214	WO 2000-US15188		20000602	<--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW						
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG						
CA 2371158	A1	20001214	CA 2000-2371158		20000602	<--
EP 1181283	A1	20020227	EP 2000-942660		20000602	<--
EP 1181283	B1	20050202				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO						
BR 2000011585	A	20020319	BR 2000-11585		20000602	<--
HU 2002002897	A2	20021228	HU 2002-2897		20000602	<--
HU 2002002897	A3	20041228				
JP 2003501420	T	20030114	JP 2001-501601		20000602	<--
EE 200100659	A	20030217	EE 2001-659		20000602	<--
AU 778071	B2	20041111	AU 2000-57254		20000602	
AT 288424	T	20050215	AT 2000-942660		20000602	
ES 2234628	T3	20050701	ES 2000-942660		20000602	
US 20020025976	A1	20020228	US 2001-783584		20010215	<--
US 6620828	B2	20030916				
ZA 2001008291	A	20021009	ZA 2001-8291		20011009	<--
NO 2001005045	A	20020204	NO 2001-5045		20011017	<--
IN 2001MN01339	A	20050304	IN 2001-MN1339		20011031	
MX 2001012483	A	20020730	MX 2001-12483		20011204	<--
BG 106276	A	20021031	BG 2002-106276		20020103	<--
PRIORITY APPLN. INFO.:			US 1999-137810P	P	19990604	
			US 2000-587530	B1	20000602	
			WO 2000-US15188	W	20000602	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 134:42124
GI



I



II

AB The title compds. [I; R1 = H, (un)substituted alkyl, cycloalkyl, etc.; R2 = OH, halo, CN, etc.; X = C, N; Q = a divalent radical having 2 or 3 atoms selected from C, N, O, S, CR5, NR5 (wherein R5 = OH, halo, CN, etc.) which together with C* and N* form a 5-6 membered (non)aromatic ring] which modulate and/or inhibit the activity of certain protein kinases (biol. data were given), and are useful in treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, were prepared and formulated. E.g., a multi-step synthesis of diaminothiazole II was given. The compds. I and pharmaceutical compns. containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation.

IT 312762-37-1P 312762-39-3P 312762-49-5P
312762-86-0P 312763-67-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaminothiazoles for inhibiting protein kinases)

RN 312762-37-1 HCAPLUS

CN Carbamic acid, [3-[5-[4-amino-2-(phenylamino)-5-thiazolyl]-1,2,4-oxadiazol-3-yl]-4-methylphenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 312762-39-3 HCAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[3-[5-[4-amino-2-(phenylamino)-5-thiazolyl]-1,2,4-oxadiazol-3-yl]-4-methylphenyl]-1-ethyl-3-methyl- (CA INDEX NAME)



RN 312762-49-5 HCAPLUS
CN Benzamide, N-[3-[5-[4-amino-2-(phenylamino)-5-thiazolyl]-1,2,4-oxadiazol-3-yl]-4-methylphenyl]-3-methoxy- (CA INDEX NAME)



RN 312762-86-0 HCAPLUS
CN Carbamic acid, [3-[4'-amino-2'-(phenylamino)[2,5'-bithiazol]-4-yl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 312763-67-0 HCAPLUS

CN 2,4-Thiazolediamine, N2-phenyl-5-(2-pyridinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 20 THERE ARE 20 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1999:297304 HCAPLUS
DOCUMENT NUMBER: 130:338100
TITLE: Preparation of thiazoles as adenosine A3 receptor antagonists
INVENTOR(S): Ohkawa, Shigenori; Kimura, Hiroyuki; Kanzaki, Naoyuki
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9921555	A2	19990506	WO 1998-JP4837	19981026 <--
WO 9921555	A3	19990722		
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2302417	A1	19990506	CA 1998-2302417	19981026 <--
AU 9896480	A	19990517	AU 1998-96480	19981026 <--
JP 11193281	A	19990721	JP 1998-303623	19981026 <--
EP 1027050	A2	20000816	EP 1998-950388	19981026 <--
EP 1027050	B1	20040114		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AT 257703	T	20040115	AT 1998-950388	19981026
US 6436966	B1	20020820	US 2000-463639	20000127 <--
US 6620825	B1	20030916	US 2002-161181	20020603 <--

PRIORITY APPLN. INFO.:
JP 1997-294485 A 19971027
WO 1998-JP4837 W 19981026
US 2000-463639 A3 20000127
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 130:338100

GI



I

AB The title compds. [I; R1 = H, alkyl, (un)substituted heterocyclyl, etc.; at least one of R2 and R3 = H, (un)substituted pyridyl, aryl, and the other = (un)substituted pyridyl; X = S which may be oxidized, O, NH, N(alkyl), N(acyl)] and their salts, useful as prophylactic and therapeutic agents for asthma, allergosis, inflammation, etc., were prepared and formulated. Thus, thiazole I [R1 = NHCOMe; R2 = 3-pyridyl; R3 = 4-MeOC6H4; X = S] which showed IC50 of 0.27 nM against adenosine A3 receptor binding, was prepared in 82% yield starting with [(4-methoxyphenyl)-5-(3-pyridyl)-1,3-thiazol-2-yl]amine.

IT 97422-54-3P 97422-55-4P 97422-56-5P
224038-79-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazoles as adenosine A3 receptor antagonists)

RN 97422-54-3 HCAPLUS

CN 2-Thiazolamine, 4-(4-methoxyphenyl)-N-phenyl-5-(3-pyridinyl)- (CA INDEX NAME)



RN 97422-55-4 HCAPLUS

CN 2-Thiazolamine, N-phenyl-5-(3-pyridinyl)-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 97422-56-5 HCAPLUS

CN Phenol, 4-[2-(phenylamino)-5-(3-pyridinyl)-4-thiazolyl]- (CA INDEX NAME)



RN 224038-79-3 HCAPLUS
CN 2-Thiazolamine, 4-(4-methoxyphenyl)-N-phenyl-5-(4-pyridinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (26 CITINGS)
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1985:454070 HCAPLUS
DOCUMENT NUMBER: 103:54070
ORIGINAL REFERENCE NO.: 103:8717a,8720a
TITLE: Preparation of 5-pyridyl-1,3-thiazole derivatives and their uses in pharmaceutical compositions
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 60058981	A	19850405	JP 1983-167042	19830909 <--
EP 149884	A2	19850731	EP 1984-305789	19840823 <--
EP 149884	A3	19860730		
EP 149884	B1	19921216		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
AT 83483	T	19930115	AT 1984-305789	19840823 <--
AU 8432433	A	19850314	AU 1984-32433	19840827 <--
AU 567754	B2	19871203		

US 4612321	A	19860916	US 1984-647436	19840905 <--
HU 37424	A2	19851228	HU 1984-3401	19840907 <--
HU 201753	B	19901228		
CA 1255663	A1	19890613	CA 1984-462626	19840907 <--

PRIORITY APPLN. INFO.:
JP 1983-167042 A 19830909
JP 1984-77819 A 19840417
EP 1984-305789 A 19840823

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 103:54070

GI



AB The title thiazole derivs. (I; R = cycloalkyl, cyclic amino, amino substituted with alkyl, Ph, Ac, etc., alkyl substituted with HO, CO2H, alkoxycarbonyl, etc., aryl; R1 = pyridyl optically substituted with alkyl; R2 = Ph optionally substituted with alkoxy, alkyl, HO, halo, or methylenedioxy) and their salts, useful in pharmaceutical compns., were prepared I were effective antiinflammation in rats, analgesics at 25-50 mg/kg in mice, and antiulcers at 50 mg/kg in rats. Thus, 0.4 mL Et3N was added to a suspension of 242 mg MeNHCSNH2 and 1.0 g II·HBr in MeCN and refluxed 3 h to give 85% I (R = MeNH, R1 = 3-pyridyl, R1 = 4-MeOC6H4).

IT 97422-54-3P 97422-55-4P 97422-56-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 97422-54-3 HCAPLUS

CN 2-Thiazolamine, 4-(4-methoxyphenyl)-N-phenyl-5-(3-pyridinyl)- (CA INDEX NAME)



RN 97422-55-4 HCAPLUS

CN 2-Thiazolamine, N-phenyl-5-(3-pyridinyl)-4-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



RN 97422-56-5 HCAPLUS
CN Phenol, 4-[2-(phenylamino)-5-(3-pyridinyl)-4-thiazolyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

L12 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1985:45931 HCAPLUS
DOCUMENT NUMBER: 102:45931
ORIGINAL REFERENCE NO.: 102:7229a,7232a
TITLE: Thiazole derivatives, and pharmaceutical compositions comprising them
INVENTOR(S): Takaya, Takao; Takasugi, Hisashi
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd. , Japan
SOURCE: Eur. Pat. Appl., 35 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
EP 117082	A2	19840829	EP 1984-300575		19840130	<--
EP 117082	A3	19870415				
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE						
US 4649146	A	19870310	US 1984-574517		19840127	<--
DK 8400410	A	19840801	DK 1984-410		19840130	<--
JP 59193878	A	19841102	JP 1984-16887		19840131	<--
JP 05079677	B	19931104				
US 4735957	A	19880405	US 1986-932097		19861118	<--
PRIORITY APPLN. INFO.:			GB 1983-2591	A	19830131	
			GB 1983-25684	A	19830926	
			US 1984-574517	A3	19840127	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 102:45931
GI



I



II

AB Blood pressure regulating, cardiotonic, and antiulcer thiazoles I [R = H, OH, alkyl, pyridyl, (un)substituted amino, guanidino; R1 = alkyl, carboxy, carboxy derivs., CH2OH, CH:NOH, halomethyl, alkylthiomethyl, (un)substituted alkenyl; R2 = alkyl, haloalkyl, (un)substituted N-containing heterocyclyl; n = 0, 1] were prepared (about 130 compds.). Thus R3CH2COCO2Et (R3 = pyridine-N-oxide-4-yl) was chlorinated and treated with PhNHCSNH2 to give the cyclocondensation product, thiazole II (X = O). Treating II (X = O) with PCl3 gave the deoxygenated product II (X = electron pair) (III). At 1 mg/kg i.v. in Heidenhain pouch dogs, III gave 95.1% inhibition of acid output.

IT 94284-73-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antiulcer activity of)

RN 94284-73-8 HCAPLUS

CN 4-Thiazolecarboxylic acid, 2-(phenylamino)-5-(4-pyridinyl)-, ethyl ester (CA INDEX NAME)



IT 94284-34-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and cardiotonic activity of)

RN 94284-34-1 HCAPLUS

CN 2-Thiazolamine, 4-methyl-N-phenyl-5-(4-pyridinyl)- (CA INDEX NAME)



IT 94284-53-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deoxygenation of, with phosphorus trichloride)
RN 94284-53-4 HCAPLUS
CN 4-Thiazolecarboxylic acid, 5-(1-oxido-4-pyridinyl)-2-(phenylamino)-, ethyl ester (CA INDEX NAME)



IT 94284-35-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 94284-35-2 HCAPLUS
CN 2-Thiazolamine, 4-methyl-N-phenyl-5-(3-pyridinyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)

L12 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1983:422230 HCAPLUS
DOCUMENT NUMBER: 99:22230
ORIGINAL REFERENCE NO.: 99:3585a,3588a

TITLE: Cephalosporin derivatives
INVENTOR(S): Farge, Daniel; Le Roy, Pierre; Moutonnier, Claude; Peyronel, Jean Francois; Plau, Bernard
PATENT ASSIGNEE(S): Rhone-Poulenc Sante, Fr.
SOURCE: Eur. Pat. Appl., 73 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 72756	A1	19830223	EP 1982-401532	19820813 <--
EP 72756	B1	19851023		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
FR 2511376	A1	19830218	FR 1981-15805	19810817 <--
FR 2511376	B1	19831110		
AT 16186	T	19851115	AT 1982-401532	19820813 <--
DK 8203669	A	19830218	DK 1982-3669	19820816 <--
JP 58039686	A	19830308	JP 1982-142001	19820816 <--
HU 27937	A2	19831128	HU 1982-2629	19820816 <--
HU 187404	B	19860128		
US 4526962	A	19850702	US 1982-408712	19820816 <--
CA 1197233	A1	19851126	CA 1982-409545	19820816 <--

PRIORITY APPLN. INFO.: FR 1981-15805 A 19810817
EP 1982-401532 A 19820813
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 99:22230
GI



I



II

AB The cephems I (X = S, SO, O; R = acyl, sulfonyl; R1 = CHR3CHO; R2 = protective group; R3 = halogen) were prepared Thus I (X = S, R = Me3CO2C, R1 = CH:CHNMe2, R2 = CHPh2) was brominated to give I (X = S, R = Me3CO2C, R1 = CHBrCHO, R2 = CHPh2) as a mixture of epimers which was cyclized with AcNHCSNH2, deblocked, acetylated with 2-thienylacetyl chloride, and hydrolyzed to give II.
IT 86109-06-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acylation of)
RN 86109-06-0 HCAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-amino-8-oxo-3-[2-(phenylamino)-5-thiazolyl]-, diphenylmethyl ester, (6R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 86109-05-9P 86109-07-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)
RN 86109-05-9 HCAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(1,1-dimethylethoxy)carbonyl]amino]-8-oxo-3-[2-(phenylamino)-5-thiazolyl]-, diphenylmethyl ester, (6R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 86109-07-1 HCAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 8-oxo-3-[2-(phenylamino)-5-thiazolyl]-7-[(2-thienylacetyl)amino]-, diphenylmethyl ester, (6R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 86114-45-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 86114-45-6 HCAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
8-oxo-3-[2-(phenylamino)-5-thiazolyl]-7-[(2-thienylacetyl)amino]-,
(6R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1983:422225 HCAPLUS
DOCUMENT NUMBER: 99:22225
ORIGINAL REFERENCE NO.: 99:3585a,3588a
TITLE: Cephalosporin derivatives and pharmaceutical compositions containing them
INVENTOR(S): Farge, Daniel; Le Roy, Pierre; Moutonnier, Claude; Peyronel, Jean Francois; Plau, Bernard
PATENT ASSIGNEE(S): Rhone-Poulenc Sante, Fr.
SOURCE: Eur. Pat. Appl., 126 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 72755	A1	19830223	EP 1982-401531	19820813 <--
EP 72755	B1	19850821		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
FR 2511375	A1	19830218	FR 1981-15804	19810817 <--
FR 2511375	B1	19831110		
AT 15045	T	19850915	AT 1982-401531	19820813 <--

JP 58041886	A	19830311	JP 1982-142002		19820816 <--
US 4496560	A	19850129	US 1982-408676		19820816 <--
PRIORITY APPLN. INFO.:			FR 1981-15804	A	19810817
			EP 1982-401531	A	19820813

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 99:22225; MARPAT 99:22225

GI



I



II

AB Cephalosporins I (R = furyl, thienyl, 2-oxo-1,3-dithiol-4-yl, Ph, 4-HOC6H4, PhO, Cl2C6H3S; R1 = H, NH2; R2 = H, alkylthio, amino, pyridiniumylmethyl; R3 = H; X = O, S) were prepared Thus II (R4 = CH:CHNMe2) was brominated to give II (R4 = CHBrCHO) which was cyclized with AcNHCSNH2 to give II (R4 = 2-acetylamino-5-thiazolyl). The latter compound was deblocked and acylated to give I (R = 2-thienyl, R1 = H, R2 = NHAc, R3 = CHPh2, X = S) which was hydrolyzed to the acid with HCO2H.

IT 86109-06-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acylation of)

RN 86109-06-0 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-amino-8-oxo-3-[2-(phenylamino)-5-thiazolyl]-, diphenylmethyl ester, (6R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 86109-05-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deblocking of)

RN 86109-05-9 HCAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(1,1-dimethylethoxy)carbonyl]amino]-8-oxo-3-[2-(phenylamino)-5-thiazolyl]-, diphenylmethyl ester, (6R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 86109-07-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)
RN 86109-07-1 HCAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 8-oxo-3-[2-(phenylamino)-5-thiazolyl]-7-[(2-thienylacetyl)amino]-, diphenylmethyl ester, (6R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 86114-45-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 86114-45-6 HCAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 8-oxo-3-[2-(phenylamino)-5-thiazolyl]-7-[(2-thienylacetyl)amino]-, (6R-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L12 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1971:87957 HCAPLUS
DOCUMENT NUMBER: 74:87957
ORIGINAL REFERENCE NO.: 74:14273a,14276a
TITLE: 2-(Lithiummethyl)-4,5-dianisylthiazole
INVENTOR(S): Lednicer, Daniel
PATENT ASSIGNEE(S): Upjohn Co.
SOURCE: U.S., 7 pp. Division of U.S. 3,458,526
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3560514	A	19710202	US 1968-768519	19681017 <--

PRIORITY APPLN. INFO.: US 1968-768519 A 19681017
AB The disclosure is the same, but the claims are different.
IT 24827-43-8P, Thiazole, 2-anilino-4,5-bis(p-methoxyphenyl)-
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 24827-43-8 HCAPLUS
CN 2-Thiazolamine, 4,5-bis(4-methoxyphenyl)-N-phenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L12 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1971:87951 HCAPLUS
DOCUMENT NUMBER: 74:87951
ORIGINAL REFERENCE NO.: 74:14273a,14276a
TITLE: 2-Substituted-4,5-dianisylthiazoles
INVENTOR(S): Lednicer, Daniel
PATENT ASSIGNEE(S): Upjohn Co.
SOURCE: U.S., 7 pp. Division of U.S. 3,458,526
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 3558644	A	19710126	US 1968-768538		19681017 <--
PRIORITY APPLN. INFO.:			US 1968-768538	A	19681017

AB The disclosure is the same, but the claims are different.

IT 24827-43-8P, Thiazole, 2-anilino-4,5-bis(p-methoxyphenyl)-
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 24827-43-8 HCAPLUS

CN 2-Thiazolamine, 4,5-bis(4-methoxyphenyl)-N-phenyl- (CA INDEX NAME)



L12 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1970:31777 HCAPLUS

DOCUMENT NUMBER: 72:31777

ORIGINAL REFERENCE NO.: 72:5821a,5824a

TITLE: 2-Amino-4,5-bis(p-methoxyphenyl)thiazoles useful for treating inflammatory conditions and in antiviral applications

INVENTOR(S): Lednicer, Daniel

PATENT ASSIGNEE(S): Upjohn Co.

SOURCE: U.S., 7 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 3458526	A	19690729	US 1966-581747		19660926 <--
GB 1188846	A	19700422	GB 1967-1188846		19670905 <--
FR 1557679	A	19690221	FR 1967-1557679		19670925 <--
BE 704312	A	19680326	BE 1967-704312		19670926 <--
PRIORITY APPLN. INFO.:			US 1966-581747	A	19660926

GI For diagram(s), see printed CA Issue.

AB Title compds. (I) are prepared by reacting α-bromodeoxyanisoin (II) with a thioamide. Thiouareas are prepared by known means, e.g. reacting an amine with CS2 in the presence of a base, e.g. Et3N, followed by ClCO2Et to give the isothiocyanate and treating this with NH3 to give the corresponding thiourea, e.g. decylthiourea, m. 94-9° (MeOH); p-anisylthiourea, m. 208-10.5° (MeOH); p-carbethoxyphenylthiourea, m. 149-51° (Skellysolve B); and p-chlorobenzylthiourea, m. 136-9° (Me2CO-Skellysolve B). II (10 g) and 2.30 g thiourea in 150 ml absolute EtOH is refluxed 3.5 hr to give 7.66 g I, m. 209-10.5° (Me2CO). Also prepared were the following I (R and m.p. given): Bu,

155-8° (Skellysolve B); decyl, 79-2° (aqueous MeOH); allyl, 128-31° (aqueous MeOH); p-chlorobenzyl, 182-5° (MeCN); Ph, 175-8° (aqueous MeOH); p-methoxyphenyl, 182-5.5° (aqueous Me2CO); p-carbethoxyphenyl, 144-8° (aqueous EtOH); Ac, 193-5° (aqueous MeOH); Bz,; p-methoxybenzoyl. Other compds. are disclosed but not characterized.

IT 24827-43-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 24827-43-8 HCAPLUS

CN 2-Thiazolamine, 4,5-bis(4-methoxyphenyl)-N-phenyl- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	110.13	484.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-13.94	-13.94

STN INTERNATIONAL LOGOFF AT 12:57:50 ON 23 NOV 2009